These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35803533)

  • 1. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody.
    Liu J; Wang P; Huang B; Cheng Q; Duan Y; Chen L; Ma T; Zhu C; Li D; Fan W; Yu M
    Int J Pharm; 2022 Aug; 624():121969. PubMed ID: 35803533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.
    Ba H; Dai Z; Zhang Z; Zhang P; Yin B; Wang J; Li Z; Zhou X
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting transmembrane TNF-α suppresses breast cancer growth.
    Yu M; Zhou X; Niu L; Lin G; Huang J; Zhou W; Gan H; Wang J; Jiang X; Yin B; Li Z
    Cancer Res; 2013 Jul; 73(13):4061-74. PubMed ID: 23794706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for targeting triple-negative breast cancer.
    Chaudhari D; Kuche K; Yadav V; Ghadi R; Date T; Bhargavi N; Jain S
    Drug Deliv Transl Res; 2023 Apr; 13(4):1074-1087. PubMed ID: 36528709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
    Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
    Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
    J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
    Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
    Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancer.
    Sharma R; Yadav V; Jha S; Dighe S; Jain S
    Carbohydr Polym; 2024 Aug; 338():122196. PubMed ID: 38763723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation.
    Duan T; Xu Z; Sun F; Wang Y; Zhang J; Luo C; Wang M
    Biomed Pharmacother; 2019 Sep; 117():109121. PubMed ID: 31252265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
    Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
    J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer.
    Wang L; Zhao C; Lu L; Jiang H; Wang F; Zhang X
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells.
    Gote V; Sharma AD; Pal D
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
    Zhao PW; Cui JX; Wang XM
    Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
    Ye J; Xia X; Dong W; Hao H; Meng L; Yang Y; Wang R; Lyu Y; Liu Y
    Int J Nanomedicine; 2016; 11():4125-40. PubMed ID: 27601899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tanshinone I improves TNBC chemosensitivity by suppressing late-phase autophagy through AKT/p38 MAPK signaling pathway.
    Tang X; Gong J; Ren L; Wang Z; Yang B; Wang W; Wang N
    Biomed Pharmacother; 2024 Aug; 177():117037. PubMed ID: 38959602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities.
    Venugopal V; Krishnan S; Palanimuthu VR; Sankarankutty S; Kalaimani JK; Karupiah S; Kit NS; Hock TT
    PLoS One; 2018; 13(11):e0206109. PubMed ID: 30408068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.